Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FPQM0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,715
Award facts
- Contract value 100% obligated
- $22,714.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on May 6, 2025, by the Defense Logistics Agency for Nucala 100 mg/ml auto-injectors, valued at $22,714.80. This firm fixed-price delivery order, with an ultimate completion date of May 7, 2025, represents a specific product request issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program. The SPE2DB IDC, valued at $499.9 million and valid through November 2026, enables DLA to issue delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables supporting Department of Defense healthcare facilities worldwide. No set-aside designation was used for this award.
Nucala (mepolizumab) is a biologic immunosuppressant medication used to treat severe eosinophilic asthma and other eosinophilic conditions. This delivery order exemplifies DMS Pharmaceutical Group's established role as a key supplier in the federal pharmaceutical supply chain, fulfilling specialized medication needs for military health facilities. The award reflects the company's consistent success in competing for pharmaceutical delivery contracts with DLA and demonstrates its capability to supply both specialty biologic medications and broader pharmaceutical product portfolios to support Department of Defense medical operations.
Quick answers
Who was awarded contract SPE2DB25FPQM0?
SPE2DB25FPQM0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on May 6, 2025.
How much is contract SPE2DB25FPQM0 worth?
The government has obligated $22,715 on SPE2DB25FPQM0.
Is contract SPE2DB25FPQM0 an order under another contract?
Yes. SPE2DB25FPQM0 is a delivery order under SPE2DB20D9127, an indefinite delivery contract.
Was contract SPE2DB25FPQM0 competed?
The extent of competition for SPE2DB25FPQM0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award